Aurobindo receives USFDA Approval for its Ciprofloxacin

Aurobindo Pharma Ltd has announced that US FDA has approved its Ciprofloxacin tablets in strengths 250, 500 and 750mg. Ciprofloxacin belongs to the class of floroquinolones. Ciprofloxacin is the generic international name for the synthetic microbicide manufactured and sold by Bayer Pharmaceutical under the brand names Cipro®, Ciproxin® and Ciprobay®.

Ciprofloxacin is considered a yardstick with which the other quinolones efficacies are measured against. Ciprofloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria.

It is used in lower respiratory infections (pneumonias), urinary tract infections, STDs, septicemias, Legionellosis and in some atypicals.

Ciprofloxacin enjoys a market of over $230 mio in the USA.

"Further the Company has informed that, the Company regrets its earlier announcement of cefpodoxime proxetil approval which was displayed by the FDA. However this product is still waiting for the official approval."

Source : Equity Bulls

Keywords